Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Awesome: Chemo + Bevacizumab +/- ICI in EGFR/ALK/ROS1+ NSCLC
NCT05284539Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Apr 2022
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05284539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284539.